Abstract
Stavudine has been associated with lipoatrophy and hyperlactatemia, and its removal might improve morphological and metabolic changes. In a prospective case-control study, serum lactate levels and lipoatrophy were examined after replacing stavudine by abacavir in patients on successful antiretroviral therapy. This intervention was safe and provided significant reductions in lactate levels over 6 and 12 months. A trend towards an improvement of lipoatrophy was also noted.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
